Market capitalization | $54.92m |
Enterprise Value | $30.55m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.66 |
P/S ratio (TTM) P/S ratio | 1.18 |
P/B ratio (TTM) P/B ratio | negative |
Sales growth (TTM) Sales growth | -44.24% |
Turnover (TTM) Turnover | $46.38m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
2 Analysts have issued a Cidara Therapeutics, Inc. forecast:
2 Analysts have issued a Cidara Therapeutics, Inc. forecast:
Dec '23 |
+/-
%
|
||
Net profit | -23 -23 |
23%
23%
|
|
Depreciation and amortization | 0.12 0.12 |
14%
14%
|
|
Share compensation | 3.06 3.06 |
13%
13%
|
|
Operating cash flow | -22 -22 |
21%
21%
|
|
Investments | 0.51 0.51 |
325%
325%
|
|
Dividend paid | - - |
-
|
|
Free cash flow | -23 -23 |
20%
20%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. Its product pipeline includes Rezafungin and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Jeffrey Stein |
Employees | 69 |
Founded | 2012 |
Website | www.cidara.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.